ReviewCureus2026
SGLT2 Inhibitors in Autosomal Dominant Polycystic Kidney Disease: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder, with tolvaptan remaining the primary disease-modifying therapy. SGLT2 inhibitors have demonstrated robust renoprotection across the chronic kidney disease (CKD) spectrum, yet patients with ADPKD have been systematically excluded from pivotal trials due to concerns over vasopressin-mediated cystogenesis. This systematic review and meta-analysis aimed to pool available evidence on SGLT2 inhibitor use in patients with ADPKD. This systematic review and meta-analysis were registered with PROSPERO (CRD420261324155) and conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta‑Analyses (PRISMA) guidelines. Five databases were searched through February 2026 for studies including ADPKD patients receiving any SGLT2 inhibitor. Quality was assessed using the Risk of Bias 2 (RoB2), Newcastle-Ottawa Scale, and Joanna Briggs Institute (JBI) tools, depending on the study design. Eight studies encompassing 3,180 patients were included, comprising one randomized controlled trial (RCT), one target trial emulation study, and six retrospective observational studies. In comparative analyses, SGLT2 inhibitor use was associated with a statistically significant attenuation of estimated glomerular filtration rate (eGFR) decline (pooled mean difference {MD}: 1.344 mL/min/1.73 m²/year; 95% CI: 0.836-1.852). A significant hemoglobin increase was observed in both comparative (MD: 0.66 g/dL) and single-arm analyses (MD: 0.55 g/dL). Subgroup analyses suggested a greater eGFR benefit in non-diabetic patients, though differences were not statistically significant. Our findings suggest that SGLT2 inhibitors may attenuate eGFR decline and improve hemoglobin in ADPKD, with the initial eGFR dip representing a class effect rather than harm, supporting their prospective evaluation in dedicated randomized trials. These findings should be interpretedwith cuchion the predominantly observational study designs, heterogeneous patient populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.